1. Home
  2. NOMA vs BYSI Comparison

NOMA vs BYSI Comparison

Compare NOMA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOMA

NOMADAR Corp.

N/A

Current Price

$3.55

Market Cap

65.4M

ML Signal

N/A

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$1.55

Market Cap

58.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOMA
BYSI
Founded
2023
2010
Country
United States
United States
Employees
8
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.4M
58.4M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NOMA
BYSI
Price
$3.55
$1.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4K
14.4K
Earning Date
05-22-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$1.18
52 Week High
$10.00
$3.44

Technical Indicators

Market Signals
Indicator
NOMA
BYSI
Relative Strength Index (RSI) 49.40 52.88
Support Level $3.35 $1.46
Resistance Level $4.69 $1.75
Average True Range (ATR) 0.42 0.18
MACD 0.03 0.01
Stochastic Oscillator 79.55 80.65

Price Performance

Historical Comparison
NOMA
BYSI

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: